共 134 条
[1]
Wild S(2004)Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 1047-1053
[2]
Roglic G(2009)Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors Cleve Clin J Med 76 S28-S78
[3]
Green A(2009)Incretin-based therapies for type 2 diabetes mellitus Nat Rev Endocrinol 5 262-269
[4]
Sicree R(2011)The current status of exenatide once weekly Clin Med Insights Ther 3 221-232
[5]
King H(2006)The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696-1705
[6]
Jaime A(2008)Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 1240-1250
[7]
Davidson MD(2009)Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in zucker diabetic fatty (ZDF) rats Pharm Res 26 2504-2512
[8]
Lovshin JA(2002)Peptide acylation in poly(ahydroxy esters) Pharm Res 19 175-181
[9]
Drucker DJ(2005)Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation Int J Pharm 297 50-61
[10]
Kulasa KM(2003)Acylation of peptides by lactic acid solutions Eur J Pharm Biopharm 55 27-33